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Abstract
Bladder cancer (urothelial carcinoma) is the most common tumor of the urinary tract. 
It occurs more frequently among men about 65 years old on average. Two forms of the 
tumor are known: a non–muscle-invasive one and a muscle-invasive one. The latter turns 
out to be very aggressive with a survival of 5 years average. The non–muscle-invasive 
form frequently recurs (60–70%) and in 15% of cases, it progresses into the invasive 
form. The diagnosis is made mainly by cystoscopy and urine cytology. A high number of 
researches were dedicated in order to find a simple test using voided urine to frequently 
monitor possible tumor recurrence. During the last 10 years, many tests were proposed 
concerning either special proteins of which the most common are the bladder tumor anti-
gen (BTA) and the nuclear matrix protein 22 (NMP22) or the presence of genetic muta-
tions [most frequently, fibroblasts growth factor receptor 3 (FGFR3) and TP53], alteration 
of DNA methylation, chromatin structure and, more recently, the presence of specific 
micro-RNA. Recently the analysis of lipids present in voided urine showed a difference 
in fatty acids between healthy individuals and those affected by non-invasive forms. 
These markers appear to have a high specificity and sensitivity: a deepening of these 
results could lead to the development of a test that avoids invasive treatment and the 
cost of cystoscopy.
Keywords: bladder cancer, bladder cancer screening, urinary markers, DNA mutations, 
lipid metabolism
1. Introduction
1.1. Epidemiology
Urothelial carcinoma of the bladder (BC) is one of the most common urogenital cancers, 
and according with the American Cancer Society in 2016, it accounts for about 5% of all 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativeco mons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
new cancers in the USA [1]. Chances for men to suffer from BC are three to four times higher 
than for women. This trend does not seem to be simply due to differences in lifestyle between 
the sexes (smoke, occupation). Perhaps, women are more protected from this disease than 
men because estrogen does not stimulate or (maybe) encourage the inhibition of oncogen-
esis [2]. This fact is supported by both in vivo experiments and data concerning mortality 
incidence [3]. Usually the first diagnosis is performed between 65 and 70 years, but it may 
occur earlier [2].
1.2. Etiology
Tobacco smoking is the major risk factor for bladder cancer; in fact, smokers develop bladder 
cancer four times more than non-smokers [4]. Long time smokers have a higher risk of getting 
sick, and this trend remains even in former smokers up to 20 years [2, 4]. The process that leads 
to carcinogenesis has not yet been described in detail nor has there been a clear definition as 
to which of the 60 carcinogens found in tobacco smoke are directly involved with cancer 
development [5]. However, some free radicals seem to have clear links with tumor develop-
ment [5]. A linear relationship was found between smoking status and 4-ABPDNA adduct 
formation and an increase in alterations in p53 tumor suppressor gene (TSG) expression [6]. 
Metabolism of arylamines are also involved in bladder carcinogenesis. In fact, N-hydroxy 
metabolites are filtered into the bladder lumen and hit the epithelial tissue, thereby triggering 
a process of tumorigenesis. The processes of detoxification, catalyzed by N-acetyltransferase, 
are under genetic control. The risk of developing bladder cancer is stronger in individuals 
with N-acetyltransferase-2 slow acetylators. There is a strict relationship between environ-
mental exposure and genetic risk factor [7, 8]. Therefore, the link between smoking and suf-
fering from bladder cancer seems to be weaker than the one between smoking and developing 
respiratory tract tumors. In fact, there are populations with high smoking rates but low blad-
der cancer rates [2]. Certain occupational groups are at increased risk of developing bladder 
cancer because of their chronic exposure to chemical agents. Also, in this case, the probability 
of developing a bladder tumor depends on an individual susceptibility to this disease [9]. 
However, some workers mainly employed in textile and tire industries are at increased risk. 
Several substances, such as naphthylamine, 4-aminobiphenyl (ABP), and benzidine, were 
unambiguously associated with bladder cancer and are now banned. Other substances such 
as ortho-toluidine, polychlorinated biphenyls, formaldehyde, asbestos, and solvents such as 
benzene, dioxane, and methylene chloride are considered strong candidates for bladder car-
cinogens. Other risk factors for the development of a bladder cancer are chronic infection or 
irritation of the bladder, which causes an involuntary contraction of the bladder muscles that 
results in an urgent, uncontrollable need to urinate. A higher possibility of developing genetic 
mutations is also favored by an increased cell proliferation due to infections and inflamma-
tory processes that favor the formation of nitrite and nitrosamines [2]. The intake of analgesics 
that contain phenacetin or cyclophosphamide are also correlated with an increased risk of 
developing urothelial carcinoma. Travis et al. found that the risk of developing bladder can-
cer following therapy with cyclophosphamide increased by 4.5-fold and was dependent upon 
a cumulative dose [10]. A study concerning the risk of bladder cancer in women found that 
radiotherapy in the pelvic area for treatment of ovarian cancer is a potential risk factor [11]. 
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Infection (in the Middle East) with parasites such as Bilharzia and Schistosoma haematobium is 
also a known risk factor for bladder cancer [12, 13]. Rare cases of hereditary bladder cancer 
were found to be related to a mutation in the retinoblastoma tumor suppressor gene [2, 14].
1.3. Pathology
The most common bladder tumors in Western countries are urothelial transitional cell carci-
noma (that counts over 90% of total cases), but there are other less common forms of tumor: 
squamous cell carcinoma, adenocarcinoma and neuroendocrine tumors [4]. Schistosomiasis 
(Schistosoma haematobium), which is endemic in Africa and in the Middle East, causes chronic 
granulomatous cystitis. This condition favors the development of squamous metaplasia of 
the transitional epithelium, which can cause squamous cell carcinoma [15]. Adenocarcinoma 
begins in glandular cells that are found in the lining of the bladder and is a very rare type of 
bladder cancer [4, 16].
1.4. Staging
Cancer that is in the lining of the bladder is known as non–muscle-invasive bladder cancer 
(NMIBC), and about 75% of patients show this degree of severity at first diagnosis [4]. These 
comprise papillary tumors designated Ta (urothelial) and T1 (extending into the lamina pro-
pria) or carcinoma in situ (CIS), a flat erythematous lesion with a propensity to progress to 
muscle-invasive disease (MIBC). This is a very aggressive cancer with a life expectancy of 
around 5 years. In fact, during stages T2–T4, the cancer spreads to the muscle layer of the 
bladder, invades the muscle wall of the bladder, and then disseminates to nearby organs and 
lymph nodes [4, 16].
Since 2002, a universal staging system can be used, namely, the TNM classification (tumor, 
lymph nodes, and metastasis). It is very important to be able to define a classification system 
that is easy to use and reproducible, because it can be crucial to adopt the most appropriate 
therapy and to predict prognosis [2].
1.5. Signs and symptoms
In most cases, lower urinary tract symptoms and hematuria are the most common early 
symptoms (85% of patients). Other symptoms include changes in bladder habits, increase in 
urinary frequency, bladder irritability, and dysuria. Symptoms of advanced bladder cancer 
are weight loss, abdominal pain, and renal impairment secondary to ureteric obstruction [2].
1.6. Bladder cancer diagnosis and surveillance
Cystoscopy is a diagnostic procedure to examine directly the bladder and is considered the 
current gold standard for diagnosis and surveillance [4]. This type of examination allows for 
a possible biopsy that can provide important information about tumors regarding the dif-
ferent developmental stages [17]. It has the disadvantage of expense and is rather invasive. 
Nevertheless, bladder cancer has a very high cost per patient because NMIBCs have a low 
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progression rate, but are characterized by a high recurrence rate (50–70% within 5 years). 
For this reason, patients need frequent and expensive surveillance protocols [18, 19]. Despite 
a correct treatment, some patients may develop muscle-invasive disease that has a high malig-
nant potential and is associated with considerable progression and cancer death rates.
A chemical dipstick for hematuria offers another diagnostic test. Unfortunately, hematuria 
from bladder cancer may be intermittent, and it occurs also in people who do not have bladder 
cancer. Furthermore, the detection of the disease may be uncertain and may require repetitive 
screening [2]. Intravenous urography (IVU) is a diagnostic test in patients with hematuria. 
It is very specific for upper tract surveillance and diagnosis while the early detection of small 
urothelial tumors may be particularly difficult to visualize.
Computed tomography (CT) scanning is useful to identify lesions within the ureter, renal 
pelvis, and renal parenchyma, but is not specific.
Urine-based cytology is more useful for patients who have a history of urinary tract cancer. 
This test may be ordered to screen patients who are at high risk for bladder cancer and as an 
adjunct in long-term surveillance protocols [2, 17].
1.7. Urine cytology
Urine cytology is the most commonly used diagnostic technique in clinical practice. Recently, 
more research on other urine-based markers has been done [20].
Urinary cytopathology is a test used to detect bladder cancer and inflammatory diseases 
of the urinary tract. It is based on the interpretation of morphological changes in disag-
gregated cells. Even in the presence of a negative cystoscopic examination, morphological 
changes such as increased size, increased nuclear-to-cytoplasmic ratio, nuclear pleomor-
phism, coarse and irregular chromatin ,and frequent mitotic figures are features associated 
with a higher risk for bladder cancer [18, 21]. This kind of analysis requires a professionally 
trained and experienced cytopathologist. Incorrect sample collection and processing can 
adversely affect the accuracy of the results [2]. The possibility of obtaining false positive is 
very high with intravesical therapy, radiation treatment, and infection, which are able to 
alter the results [18].
This method is not suitable for screening patients because it is not very sensitive in the cases of 
low-grade tumors. In fact, it is not easy to identify tumor cells in urine specimens of patients 
with noninvasive low-grade carcinoma. These cells have particular characteristics that are not 
always similar to the malignant tumor cells. The early stage, dysplasia, is characterized by 
the formation of flat, fibrovascular stalks that cannot be identified as neoplastic formations in 
histological sections.
Urinary cytology is mainly indicated for the detection of high-grade and high-stage disease 
that shows more recognizable features (nuclear pleomorphism, coarsely clumped chromatin, 
and large nucleoli) [2]. In fact, urinary cytological analysis can detect carcinoma in situ (CIS) 
with a sensitivity of 80–90% and a specificity of 98–100% because it consists of cells that are 
significantly abnormal. Urinary cytology can be used in long-term surveillance programs, but 
it is an expensive technique [18].
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1.8. Biomarkers in bladder cancer
The correct treatment of patients with bladder cancer requires an early and accurate diagno-
sis, which is followed by long-term surveillance. Currently, the most effective tests that could 
diagnose and monitor the progression of the disease are cystoscopic examination, cytology, 
and histology. These techniques have promoted a dramatic decrease in the mortality associ-
ated with the disease, but they are inadequate for several reasons. They do not allow us to 
understand the molecular mechanisms underlying the tumor in question; the possibility of 
human error is quite high; they are expensive and, in the case of cystoscopy, invasive [17].
In recent years, due to improved molecular biology techniques, new classes of diagnostic and 
prognostic biomarkers have been identified. They have taken into account not only individual 
proteins but also the interactions between molecules in pathways known to be tumorigenic [22].
Tumorigenesis occurs often with a clear involvement of distinct pathways that can lead to the 
development of NMIBC or of MIBC. This feature can be used to find out new markers which 
are able to highlight the pathway involved and, hence, the type of tumor. The study of gene 
expression in bladder cancer is another type of investigation that is developing [17]. Identifying 
the ideal marker is not a simple task. Indeed, it needs to feature many requirements together: 
high sensitivity and specificity, the ability to predict the degree of tumor malignancy, lack of 
susceptibility to human errors, user-friendliness, noninvasiveness, and price convenience. It 
should not be influenced by the presence concurrently of other diseases and by the presence 
of hematuria or irritative symptoms that often occur in patients with bladder cancer [20]. An 
ideal biomarker should be also able to identify, in a clear way, the disease before its clinical 
manifestation and, at the same time, to provide accurate prognostic information [17, 23]. By 
developing non-invasive molecular assays which are able to analyze body fluids, it would be 
easier to perform a large-scale screening of individuals most at risk [20, 22]. It would be impor-
tant to be able to develop a test that can express a very strict diagnosis, which allows patient 
treatment in a personalized way. This ideal marker could relieve the inconvenience inherent 
in the use of invasive procedures to strictly necessary cases. In the last few years, the aging of 
the population has caused a dramatic rise in diseases related to age. The incidence of bladder 
cancer has increased by 36%. This is another reason why it would be useful to have an effective 
screening method, as is the case for the screening of prostate and colon cancer [20].
The following discussion illustrates the current diagnostic assays for bladder cancer and dis-
cusses some of the emerging biomarkers. Some of these studies are at a preliminary stage, but 
they appear to deserve further investigation and a mention in this text.
2. Current diagnostic assays
2.1. Urine-based assay
2.1.1. Bladder tumor antigen (BTA) assay
The original bladder tumor antigen (BTA) test is an agglutination assay that measures the level 
of a membrane protein that is released into the urine when the cancer invades the bladder wall. 
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The BTA test can be used for the detection of low-grade disease and shows a higher sensitivity 
than cytology. Unfortunately, it cannot be used in patients affected by other disorders such as 
urinary infections, stones, or benign prostatic hypertrophy (BPH). In such cases, the presence 
of concomitant diseases can lead to false-positive results [20]. To overcome this lack of preci-
sion, two other BTA tests were developed: BTA STAT and BTA TRAK. Both are immunoassays 
that can detect factor H–related protein (cFH), which is released into the urine by tumor cells 
[2, 18, 20].
BTA STAT is a qualitative dipstick test [24]. This assay has several advantages: it is fast, is inex-
pensive, and works with only a few drops of urine. The sensitivity is higher than either the 
original version of the test or cytology. The results are more accurate in cases of high-grade 
bladder cancers. Unfortunately, this test has the same problems as the original version. False-
positive results are quite common with rates of 2–5%. This assay cannot be used in patients 
with dysuria, incontinence, and hematuria [20]. Also in the case of bacillus Calmette-Guérrin 
(BCG) instillation in patients has led to a sharp drop in its accuracy, even if the treatment 
was made 2 years before. For this reason, BTA STAT cannot be used for the monitoring of 
the disease in patients who have undergone immunotherapy [20, 22]. The reasons for its low 
specificity yet its high sensitivity are still not clear. The use of BTA STAT was approved by 
the U.S. Food and Drug Administration (FDA). However, a constant monitoring of patients is 
recommended also through cystoscopy. Hence, this technique is not definitive for diagnosis, 
but it is only indicative [20, 24].
BTA TRAK is a quantitative assay: an ELISA test that detects levels of cFH [20, 22]. The cFH 
protein can be detected also in case of bladder bleeding [22]. Furthermore, other studies argue 
that cFH is definitely produced and secreted by the Kupffer cells, hepatocytes, vascular endo-
thelial cells, and platelets, but it has not been proven that bladder cancer cells secrete cFH 
[22, 25]. The BTA TRAK test shows a higher sensitivity than does either the BTA STAT test 
or cytology also for the detection of low-grade tumors. However, this test presents problems 
of low specificity for the same reasons as the BTA test. For this reason, also this test cannot 
replace urine cytology or cystoscopy. An increase of the test values is often related to the 
possibility of the development of a recurrence. BTA TRAK may be useful for quantifying the 
correct time interval between the cystoscopic analyses individually in a patient with a recur-
rence, but this assumption needs further work [20].
2.1.2. Nuclear matrix protein 22 (NMP22)
Nuclear matrix proteins (NMPs) have a structural role in cellular nuclei and are involved in 
DNA replication, transcription, RNA processing, and gene expression. In particular, NMP22 
is a specific protein of the nuclear matrix that is involved in the correct distribution of the 
genetic material to daughter cells during mitosis [20]. Two different texts to detect this pro-
tein have been developed: NMP22 test, which is a quantitative immunoassay and NMP22 
BladderChek, which is a qualitative point-of-care test. Apoptosis causes the release of this 
protein into the urine that can be detected using monoclonal antibodies. Urine of patients 
with bladder cancer contains a greater amount of this protein compared to healthy controls [2, 
18, 20]. Thus, this test provides a measure of cell turnover. The sensitivity is about 51–85% and 
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increases with the support of cytology [18]. Also other bladder diseases affect the reliability 
of this test negatively and the rate of false positive is quite high [20, 24]. NMP22 is not suit-
able to be used for screening exams; however, some studies have found positive correlations 
between NMP22 levels and the aggressiveness of the cancer. This correlation can be exploited 
to make assessments on patient prognosis [20, 26, 27]. The evaluation of NMP22 levels may 
also have predictive value for the risk of recurrence. In fact, Soloway et al. found that patients 
who exceed a threshold value of NMP22 level (20 U/ml) have a greater probability to develop 
a recurrence [28].
2.1.3. BLCA-1 and BLCA-4
BladderCancer-1/BladderCancer-4 (BLCA-1 and BLCA-4) are members of six bladder-specific 
nuclear matrix proteins (NMPs) discovered in 1996 by Getzenberg et al. [29]. These proteins 
are involved in important cellular functions such as DNA replication and RNA synthesis 
and in nuclear morphology [30]. Many NMPs are identified as specific markers for several 
cancers [31]. BLCA-1 and BLCA-4 are considered specific urinary markers of bladder cancer. 
In particular, they are associated with tumor cell proliferation, survival, and angiogenesis 
[29–31]. The expression of these factors is important to detect bladder cancer at an early stage, 
since they are expressed early in carcinogenesis [18]. BLCA-1 was originally identified from 
bladder tumor tissue, while BLCA-4 is expressed in both tumor and adjacent benign areas 
of the bladder, but not in bladders without malignancy [29, 30]. Probably they play different 
roles in the regulation of the gene expression in bladder cancer [32]. Although BCL-1 has high 
sensitivity and specificity while its role is not yet clear in the development of bladder cancer. 
BCL-4 has sensitivity and specificity higher than other urinary tumor markers. The detection 
BCL-4 expression is not affected by the presence benign bladder disorders but may increase 
in patients with spinal cord injuries. Both BCL-1 and BLCA-4 assays still need further refine-
ment and validation if they are to be included into clinical practice [30].
2.1.4. Urinary Bladder Cancer test (UBC)
Cytokeratins (CKs) are intracellular proteins in the intracytoplasmic cytoskeleton of epithe-
lial cells. They are overexpressed in bladder cancer and are released into the urine as soluble 
fragments after proteolytic degradation following cell death [18, 33]. Because of such features, 
various assays measuring the concentration of soluble cytokeratins, such as TPS for cytokera-
tin 18 and TPA for cytokeratin 8, 18, and 19, have been used to detect bladder tumors [34]. 
Immunological assays UBC-Rapid and UBC-ELISA tests are used to detect the concentration 
of a combination of cytokeratin 8 and 18 fragments [18]. The UBC-Rapid test is a qualitative 
point-of-care assay that shows a high variability of sensitivities and specificities that prob-
ably is due to the histological and clinical characteristics of bladder cancer [18, 33]. This assay 
requires no special knowledge as the case of BTA STAT and is more sensitive and specific. 
However, it has a low sensitivity in the detection of bladder cancer recurrence and cannot 
replace, but only lower, the number of cystoscopies heeded during the patient’s follow-up 
[35–37]. UBC-ELISA is a quantitative assay. It is limited by a strong possibility of human error 
and it is characterized by a high variability of sensitivity and specificity, a high false-positive 
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rates and the inability to detect low-grade tumors. Further studies are needed to assess their 
potential diagnostic role and to increase the utility of these tests for bladder tumor surveil-
lance [18].
2.1.5. CYFRA 21-1
Cytokeratin Fragments (CYFRA 21-1) is also an ELISA-based assay that detects the concen-
tration of soluble fragments of cytokeratin using two mouse monoclonal antibodies. Various 
studies on the sensitivity and specificity of the assay have reported different results. Possible 
reasons include the different tumor grade of the patient populations and the differences in 
the method of urine collection and storage [34]. The centrifugation step is very important to 
remove cells and cell debris that contains a large amount of CYFRA 21-1, though the accuracy 
of the assay is not improved yet. In fact, after centrifugation an equivalent decrease in the 
number of true positive and false positive can be observed [38]. CYFRA 21-1 is found at high 
concentrations in the urine of patients with benign diseases of the bladder. Also intravesical 
immunotherapy with BCG increased concentrations of urinary CYFRA 21-1, even after years 
of treatment, when there was no evidence of a bladder tumor. This assay has a high sensitivity 
for the detection of high-grade and CIS tumors, but it cannot be used for early detection. This 
assay shows greater accuracy for the detection of primary tumors than for the recurrence. 
Currently, it cannot be used as a substitute for cystoscopy and has achieved only an arguable 
and marginal role in daily clinical practice [34].
2.1.6. Survivin
Survivin is a member of the inhibitors of apoptosis proteins (IAP) gene family that is involved 
in apoptosis inhibition [39]. Survivin is expressed during embryonic and fetal development 
but not in normal adult tissues. It is also abundantly expressed in transformed cells and in 
many tumors. Survivin promotes an abnormal elongation of cell life that leads to an accumu-
lation of genetic mutations and can promote resistance to immune-surveillance. Researchers 
are interested in exploiting the information on survivin for diagnostic and clinical purposes. 
For this reason, they are studying its role as a promoter of carcinogenesis but also the path-
ways in which it is involved. The detection of survivin in the urine is obtained by a BioDot 
microfiltration detection system. Dots of the urine samples are blotted on nitrocellulose mem-
branes and survivin can be detected using various anti-survivin antibodies and standard 
dot blot detection reagents [40]. Survivin has a high sensitivity for detecting low-stage and 
low-grade bladder tumors often underdiagnosed by other diagnostic tests. High level of the 
urine’s survivin is associated with increased risk of bladder cancer, of tumors of higher grade, 
and of bladder cancer recurrence. This assay is more accurate than cytology tests using urine. 
Moreover, it is also more accurate than NMP22 tests and avoids false-positive results.
Survivin is present in the urine of 78% of patients with localized disease. Its level could be 
skewed in patients with either T1 or higher tumor stage than in patients with Ta disease or 
CIS. Its use in the diagnosis would require further evaluation and a deepening study of the 
signaling pathways in the bladder cancer [41].
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2.2. Cell-based assay
2.2.1. ImmunoCyt/uCyt+ assay
Fradet and Lockhard developed the immunofluorescence-based test ImmunoCyt/uCyt+ in 
1997. These are two markers that are expressed in malignant exfoliated urothelial cells and 
few normal umbrella cells and are not found in the other normal cells [17, 18, 42]. This assay 
uses a cocktail of three antibodies: the first antibody (19A211) is directed against a glycosyl-
ated carcinoembryonic antigen and is labeled red; the other two antibodies, M344 and LDQ10, 
labeled with fluorescein, are directed against mucins [18, 42]. The mucins are glycoproteins 
that are normally found on the surface of epithelial cells. In normal cells, these glycoproteins 
are found in heavily glycosylated form while in malignant cells these glycoproteins are less 
glycosylated. This test uses LDQ10 and M344 antibodies that can recognize some portions of 
the protein backbone [42]. The recognition of the results is given a lot to the cythopatholo-
gist's skill. In fact, to have a negative response, cytology slide should contain at least 500 cells 
that are negative for fluorescence while the presence of one fluorescent cell is considered 
to be positive. This assay is not very influenced by factors such hematuria or inflammatory 
conditions because it is a cellular assay. ImmunoCyt/uCyt+ has a superior sensitivity to detect 
early pathological stage than cytology. It can also improve the detection of CIS and increase 
the sensitivity of the urinary cytology [18]. However, to be valid, this assay must always be 
accompanied by cytological analysis, and it is only suitable for the surveillance of patients 
with a history of bladder cancer [18, 42].
A combination of multiple immunological tests is considered useful for diagnosis and prog-
nosis. Recently a combination of p40, GATA3, and uroplakin II (transmembrane protein) anti-
body has been proposed [43].
2.2.2. UroVysion fluorescence in situ hybridization (FISH)
UroVysion is also a fluorescence-based assay. It was developed in 2000 and is FDA approved 
as a urine marker for the diagnosis and the surveillance of bladder cancer [24]. Exfoliated 
urothelial cells are analysed exploiting the technique of fluorescence in situ hybridization 
(FISH) to detect the aneuploidy of chromosomes 3, 7, and 17 and loss of the 9p21 locus 
[17, 18]. As the case of ImmunoCyt/uCyt+ assay, this assay is quite complex and requires 
the interpretation of a skilled cytopathologist. In fact, the result is considered to be posi-
tive if either at least five cells are found with two extra chromosomes, or ten cells with 
an extra chromosome, or a homozygous deletion of 9p21 in >20% of the epithelial cells 
[24]. UroVysion has a higher sensitivity in diagnosis or recurrence of bladder cancer than 
other types of analysis. A positive result of UroVysion test, in patients who have been pre-
viously treated with BCG, can warn doctors about treatment failure. Unfortunately, this 
assay has the disadvantages of providing many false-positive results and is found to be 
more sensitive in cases of high-grade tumor than in case of low-grade disease. Thus, it 
is recommended to use UroVysion after ImmunoCyt/uCyt+ test or cytological analysis as 
a confirmatory test [18, 44].
Bladder Cancer Markers and Recent Innovations
http://dx.doi.org/10.5772/67309
71
2.2.3. DD23
DD23 is an IgG murine monoclonal antibody (MAb) derived from the immunization of 
a BALB/c mouse that recognizes a 185-kDa tumor-associated antigen. This antigen is not 
detected in normal urothelium while it is expressed in human bladder cancer cells, both 
in vitro and in vivo [45]. However, a study observed that in patients with bladder cancer, 
DD23 antigen is expressed in cancerous as well as in noncancerous cells. One theory holds 
that normal urothelial cells in response to external signals from the malignant cells express 
DD23 [45, 46]. This immune-cytochemical assay is performed using an avidin-biotin alka-
line phosphatase, with a single urothelial cell exhibiting intense immunostaining sufficient to 
make a positive call. However, there are various methods of DD23 detection [47]. For exam-
ple, Bonner et al. used a highly sensitive automated quantitative fluorescence image analy-
sis system, whereas Gilbert et al. used a commercial clinical reference laboratory-adapted 
qualitative immunocytochemistry assay with light-based microscopy [45, 46]. The cytologi-
cal analysis of urine sediment carried out using murine IgG1 monoclonal antibody (MAb) 
together with Papanicolaou (Pap) staining is difficult both from practical use and from an 
interpretative point of view. Even this technique has a higher sensitivity for the detection 
of high-grade tumors than low-grade ones [47–52]. DD23 antigen expression must be sup-
ported by cytological analysis. It can enhance the sensitivity of the cytopathology diagnosis of 
21%, especially in low-grade cancers and can increase the detection of unclassified TCC cases 
[45, 53, 54]. This assay is not very suitable for the detection of recurrence in patients who have 
previously received an intravesical therapy. DD23 can be a support of cystoscopic examina-
tion to increase the sensitivity to monitor and diagnosis recurrent bladder cancer. The use of 
this biomarker needs further clinical studies [45].
These assays are summarized in Table 1 with their characteristics.
Sensitivity Specificity Limitations
Urine-based assay
BTA STAT 53–83% 67–72% High false-positive rates.
BTA TRAK 66–72% 51–75% High false-positive rate.
Nuclear matrix protein 22 
(NMP22)
51–85% 77–96% False positive in case of hematuria or 
inflammatory bladder conditions.
BLCA-1 80% 87% It needs futher validation.
BLCA-4 89–96% 90–100% It needs futher validation.
UBC-Rapid test 36–78% 63–97% High variability of sensitivities and 
specificities. Hight false-positive rate. 
Low sensitivity in the detection of low-
grade bladder tumors.
UBC-ELISA 40–70% 63–75% Hight false-positive rate. Low 
sensitivity in the detection of low-
grade bladder tumors.
CYFRA 21-1 61–85% 75–91% False positive in case of inflammatory 
bladder conditions.
Survivin 64–83% 88–93% It needs futher validation.
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3. Nucleic acids alterations
Circulating DNA has been demonstrated in all body fluids, including urine, and it is the dem-
onstration of many tumor-related alterations, particularly for colon cancer. For this reason, 
many researches were made on urine and bladder samples in order to analyze free DNA and 
RNA fragments present. An increase in DNA was found in both the voided urine and plasma 
of patients with NMIBC with respect to non-affected patients [55]. Aggressive tumors show 
very high DNA values. Analysis of the DNA may represent a novel diagnostic tool to indicate 
the presence of residual disease or to discover aggressive forms early in the bladder cancer 
course. Analysis of the DNA showed 302 mutations of exons, 204 segmental alterations in 
genomic copy number. and 22 genomic rearrangements for a given sample [56]. Three dif-
ferent groups were identified based on the gene alterations. Group A, classified as focally 
amplified, is enriched in focal somatic mutations in many genes; group B is characterized 
by CDKN2A-deficient fibroblast growth factor receptor 3 (FGFR3) mutant defined papillary 
from the histological aspect; and group C, classified as “tumor protein p53 (TP53) cell-cycle 
mutant”, is enriched with RB1 mutations and amplifications of E2F3and CCNI [56].
It has been suggested that these differences may represent different oncogenic mechanisms. 
In non-invasive tumors, mutations were found especially in the oncogenes Harvey rat sar-
coma (HRAS), fibroblasts growth factor receptor 3 (FGFR3), and phosphatidylinositol-3-ki-
nase (PK3CA).
In invasive tumors, mutations have been found in tumor suppressor genes, especially TP53 
and retinoblastoma (RB1) [57]. The presence of the FGFR3 mutation in urine is observed for 
low-grade tumors and seems to be associated with concomitant or future recurrence [57, 58]. 
Methylation is also important: five targets were identified, including ventral and anterior 
homeobox 1 (WAX1) KCNV1, TAL1, PPOX1, and CFTR, which have a sensitivity of 88.68% 
and a specificity of 87.25%. An increase in methylation is also observed for the tumor sup-
pressor gene RUNX3 gene [59, 60]. In particular, methylation of VAX1 and LMX1A appears 
to be associated with bladder cancer recurrence. Promoter hypermethylation of some genes 
Sensitivity Specificity Limitations
Cell-based assay
ImmunoCyt/uCyt+ assay 68% 72% The test results depend on specimen 
stability and handling.
UroVysion fluorescence 
in situ hybridization (FISH)
69–75% 82–85% Low sensitivity in the detection of 
low-grade bladder tumors. Lack of 
consensus regarding criteria used to 
evaluate abnormal cells.
DD23 (*) 70.3% 59.8% It can be used as an adjunct to 
cytopathologic evaluation.
All the data derived from Ref. [17], except (*) from Ref. [23].
Table 1. Sensitivity and specificity of urine-based and cell-based assays.
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 combined with FGFR3 mutations may represent a sensitive diagnostic assay [61]. Methylation 
of the tumor suppressor gene H-cadherin (CDH13) has been reported in many cancers, and an 
increase is observed especially in Asian patients affected by bladder cancer [62]. The CDH13 
gene, located on 16q24, encodes a protein that belongs to the cadherin family [63]. CDH13, 
a tumor suppressor gene (TSG), is also called H-cadherin or T-cadherin and plays a pivotal 
role in cell–cell adhesion [64]. The expression of this gene favors the adhesion between the 
cells, thus inhibiting metastatic diffusion.
3.1. Microsatellite analysis
Microsatellites (or short tandem repeats) are repeated noncoding DNA sequences consisting 
of very short repeat units (mostly 2–4 bp each) arranged in a tandem repeat. They can be 
used as molecular markers of loci and play an essential role in the structure of chromosomes. 
Two types of microsatellite alteration are involved in many cancers: loss of heterozygosity 
due to a deletion and genomic instability due to an alteration of microsatellite repeat length 
[40, 65].
Several studies have been published on the correlation between microsatellite alterations in 
bladder transitional cell carcinoma (TCC). In particular, they have observed 17 microsatellite 
loci. The loci on chromosomes 9 and 18 have proven to be the most informative [66–69]. Saidi 
et al. compared two microsatellite loci (GSN and/or D18S51) of patients with histopathologi-
cally confirmed bladder TCC, with normal bladder mucosa and with non-malignant diseases. 
They found alterations in 46 out of 70 patients with TCC, but none in the tissue samples from 
the control group [70]. This analysis showed a sensitivity of 65.71%, and specificity of 100% 
but, according to the literature data, frequency of microsatellite alterations in urinary bladder 
TCC varies a great deal [67, 70, 71]. Unfortunately, microsatellite analysis is time-consuming, 
expensive, and requires highly trained personnel. Furthermore, Saidi et al. have not found 
a close correlation between the pathological stages as recurrence, metastasis, and death, in 
patients with TCC, followed by at least 2 years [70]. The study of the possible use of microsat-
ellites as a tumor marker is complicated also by other point of view: the correct selection of 
microsatellite loci, their polymorphic nature and ethnic differences in patient populations are 
features that affect the results between studies [70, 72].
4. Chromatin alterations
Mutations in chromatin could lead to alterations in genes involved in human carcinomas [73]. 
In high-grade bladder cancer over 2300 alterations were found as well as in genes involving 
chromatin modifiers [74]. This implies that epigenetic modulators could have a therapeu-
tic role in urothelial cancers [73]. Varticovski et al. performed comparative bio-informatic 
analysis on mutations in several previously identified genes associated with bladder cancer. 
They found mutations in TP53, RAS, and TERT genes and mutations/deletions in several 
chromatin modifiers KDM6A and MLL2/3. They found also mutations in novel sites distant 
from promoters showing a reprogramming of regulatory networks. Many of these mutations 
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occur in characteristic sites unique for each stage of the tumor progression. This feature has 
potential clinical application providing valuable new information on bladder cancer biology 
and tumor progression [74]. The coiling of DNA around nucleosome particles is the basis 
of genome organization with histone modifications being associated with both active and 
repressed regions of chromatin. Acetylation or phosphorylation may change the chromatin 
structure by altering the net positive charge of the histone proteins so changing the acces-
sibility of the underlying information sequences. Modifications of histones are reported for 
many tumors and are correlated to tumor stage and prognosis, but with contradicting results 
[75]. Histone acetylation is catalyzed by a specific enzyme family, histone acetyltransferases 
(HATs), and correlates with nucleosome remodelling and transcriptional activation, whereas 
deacetylation of histone tails is catalyzed by histone deacetylases (HDACs) induces tran-
scriptional repression through chromatin condensation [76]. Altered expression of different 
HDACs has been reported inr various human cancers [77–83]. Bladder tumor chemothera-
pies, which act as inhibitor of acetyltransferase, have shown that the decrease in tumor cel-
lular growth in vitro is due to the acetylation of histone lysine with a consequent imbalance 
between histone acetylation and de-acetylation.
4.1. Telomerase
The telomere is the terminal region of eukaryotic chromosome and is composed of highly repet-
itive DNA sequences (e.g., TTAGGG in humans). It was thought to be a non-coding region 
while recent discoveries have speculated that it is involved in the regulation of telomerase. 
Telomerase is a ribonucleoprotein organized to form a complex that includes: an RNA com-
ponent, human telomerase RNA (hTR), and telomerase reverse transcriptase (hTERT) that is 
a catalytic protein. In normal cells, DNA polymerase is not able to replicate the chromosome 
until its termination. In fact, after each DNA replication, there is a progressive shortening 
of chromosomes with a consequent loss of genetic information, which causes chromosomal 
instability and cellular senescence. Telomerase maintains telomere length in several cancer 
cells types [40]. It keeps intact chromosomes adding telomeres at the ends chromosomes, 
lengthening again the shortened telomeres. In normal cells it is active only during embryonic 
development while in most normal adult tissues its expression is repressed [84]. The expres-
sion of telomerase in tumor cells immortalize them [85]. This mechanism can be considered a 
crucial step in tumorigenesis [84].
The telomeric repeat amplification protocol (TRAP) assay is used to measure telomerase 
activity. Telomerase reaction products are detectable by several commercial kits that pro-
vide optimized sets of primers and reagents for telomerase detection. Another method 
allows measurement of hTERT mRNA levels by RT-PCR. The sensitivity of these assays 
is variable: it depends on sample manipulation but also on the presence of inflammatory 
conditions that can contaminate benign cells with telomerase activity [86–96]. The specific-
ity of both the TRAP assay and hTERT RT-PCR is also variable. Telomerase assays are not 
suitable for use in clinical settings. To overcome these problems, it requires more clinical 
trials [40].
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5. RNA messenger
The detection of (hTERT), mRNA of human telomerase reverse transcriptase, using RT-PCR 
was considered as a valid tool for a noninvasive tumor diagnosis test. However, in urine 
we can found a significant amounts of cell-free RNA and for this reason RNA tumor mark-
ers (e.g., hTERT, UPK1A, HTATIP2), cannot be used unconditionally for RT-qPCR–based 
analysis of whole urine [97]. Another system that has been intensively studied for its role 
in tumorigenesis is uPA: ETS2. The uPA promoter region contains ETS2 binding sites, a 
member of the ETS family of transcription factors. uPA mRNA content in tissue and uri-
nary protein concentrations of uPA are suitable for bladder cancer diagnostics. In the case 
of bladder cancer higher ETS2 RNA concentration it is observed compared with uPA. 
This tumor marker ratio of ETS2: uPA could be an interesting diagnostic tool [97–101]. 
Hedegaard et al. prepared a total RNA-sequencing (RNA-seq) libraries for 476 patients 
with bladder cancer at different stages (Ta, T1, in situ [CIS], MIBC). They mapped sequences 
to the human genome and then explored the heterogeneity in early-stage bladder cancer 
of 8074 genes [102]. The results were interpreted by statistical analysis and, on the basis 
of these results; the bladder tumors were sub-grouped into three major classes [102–104]. 
They found that tumors of high stage and grade were more frequently observed in classes 
2 and 3 than in class 1.
Particularly, MIBC and high-risk NMIBC were more frequently observed in the same clus-
ter 2 showing similarities. Differences in gender or smoking status do not influence the 
results [102]. Class 3 tumors show basal-like characteristics. They are mainly associated 
with repressed genes and with modifications of histones and/or chromatin. Class 1 tumors 
are characterized by a good prognosis, while class 2 shows poor prognosis and high 
expression of late cell-cycle genes, which have previously been associated with aggres-
siveness in bladder cancer [102, 105, 106]. Class 1 and class 2 tumors display different 
levels of aggressiveness. This study can be overlapped with other previous studies [105]. 
This kind of analysis could be a way for optimized surveillance programs and treatment 
selection [102].
6. Micro RNA
Micro RNA are short non-coding RNAs (18–25 nucleotides) that can change the expres-
sion of mRNA. This kind of regulation can take place directly by interaction with mRNA, 
by translation regulation of the protein product or by mRNA degradation. A single 
miRNA can regulate multiple genes or more miRNA can be involved in a single target 
(Figure 1) [107].
They can, therefore, regulate the expression of many genes and the analysis of these mol-
ecules may be important for understanding many biological processes such as epithelial to 
mesenchymal transition, which is a relevant mechanism in bladder cancer tumor develop-
ment. Micro RNAs are present in many body fluids including urine, are resistant to RNase 
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and also can be preserved for long time, so they can be determined using non-invasive meth-
ods. Many miRNAs were found in the urine, some of them might be correlated with renal or 
prostatic diseases, as well as bladder cancer [108].
Recently, a list of miRNAs detected in bladder cancer as well as their target genes has been 
reported. At the moment, a complete analysis is unavailable, but some results indicate some 
differences in relation to bladder cancer, particularly in relation to their invasiveness and 
prognosis.
An increase of miR 21, the cluster miR 183-96-1, miR 210, and miR 205 is observed to influ-
ence the epithelial-mesenchymal transition, cell growth and migration. On the other hand, a 
decrease is observed in many others, like miR 29c, miR 124, miR 409, miRs 23 family, miRs-
200 family, miR-214, that favors apoptosis and inhibit cell proliferation. miR-205 discrimi-
nates between low-grade papillary urothelial carcinoma and high grade papillary urothelial 
carcinoma, whereas miR-145 distinguished high-grade papillary urothelial carcinoma from 
infiltrating carcinoma [109]. The increase of the expression levels of miR-200c and miR-141 
in patients with bladder cancer after surgical removal of the tumor appears to return to 
normal values [110]; miR-126, miR-182, and miR-199a are the most abundant in the urine 
of bladder cancer patients with respect to the controls [107]. Ratios of miR-12 s6/miR-152 
Figure 1. Functions of mi-RNA.
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and miR-182/miR-152 are considered as makers capable of distinguishing bladder cancer 
patients from controls and patients affected by infections. Their sensitivity and specificity are 
not very high ranging from 55 to 82%. Yamada et al. found that the detection of miR-96 in the 
urine has a sensitivity of 71.8% and a specificity of 89.2% [111]. Shimizu et al. reported also 
good specificity and sensitivity by testing a methylation panel of miR9-3, miR124-2, miR124-
3, and miR 137 [112]. As regards to a prognostic evaluation, miR2103, miR214, miR152, and 
miR3187-3p are predicting a recurrence-free survival [113–115].
7. Proteins
Proteomics analysis allows the identification of proteins in the urine of patients. Some of 
these proteins such as alpha-defensin, apolipoprotein A-1 (APOA1), and alpha-1-antitrypsin 
are present in increased levels in tumor cells [116]. Metabolomic analysis allowed the iden-
tification of some metabolites associated with bladder tumors. However, the correct associa-
tion of the results with a type of tumor can be difficult to establish due to small molecule 
renal filtration.
There are several proteins that are worth further study for evaluation as new possible bio-
markers. Fibronectin is a multifunctional, extracellular matrix glycoprotein. It is produced by 
a wide variety of cells and is present in many tissues. Some studies have shown that increases 
in the urine content in case of the bladder cancer [117–119]. Clusterin is a heterodimeric 
disulfide-linked glycoprotein, implicated in a number of biological processes. It is a chaper-
one protein present in two isoforms (1 and 2) with antagonistic actions exhibiting different 
cellular locations. Clusterin gene increases its expression in bladder cancer particularly in 
invasive disease [120]. High clusterin expression is associated with poor prognosis. However, 
it is expressed in all body fluids and this feature limited its specificity. It would be neces-
sary to detect the individual expression of the two isoform rather than total clusterin levels 
[121]. Tilki et al. reported CEACAM1 (Carcinoembryonic antigen-related cell adhesion mol-
ecule 1, also known as CD66a) as a novel urinary marker for bladder cancer. Sensitivity was 
higher for MIBC than NMIBC and thougth patients with diabetes were excluded from the 
study. Furthermore, CEACAM1 immunostaining disappears in urothelium of NMIBC while 
appears in adjacent tumor-associated endothelial cells [122]. Calprotectin is a protein with 
antimicrobial properties [123]. It was suggested as a prognostic indicator because it results in 
upregulation in bladder cancer with 80% sensitivity at 92% specificity [124, 125]. However, it is 
released also by neutrophils during inflammatory processes and this feature compromises its 
accuracy [126]. Stathmin-1 and CD147 are two urinary proteins studied for their correlation 
with bladder cancer. In fact, there are reports that overexpression of stathmin-1 and CD147 
are associated with aggressive bladder cancer and a poor prognosis [127, 128]. γ-synuclein 
is involved in the pathogenesis of neurodegenerative diseases and is also used as a marker 
in breast tumors. It shows 87.5% sensitivity and 90.0% specificity. DJ-1 has been reported 
to be overexpressed in aggressive high-grade bladder cancer [129]. A pilot study found uri-
nary DJ-1 to be significantly increased only in MIBC [130]. The specificity of Apolipoprotein 
A4 for bladder cancer is not confirmed even if various apolipoproteins increase in the urine 
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of  bladder cancer patients [131]. In Kumar et al probably was overestimated the presence 
coronin-1A (a cytoskeletal protein) in urine of patient with bladder cancer [130, 132]. Orenes-
Piñero et al. realized an immunohistochemistry analysis, followed a proteomics analysis, that 
showed Reg-1 (lithostathine-1-alpha) overexpression in bladder tumors [133]. Urinary levels 
of matrix metallopeptidase 9 (MMP9) are elevated in many cases of invasive bladder cancer. 
However, it shows a modest sensitivity and specificity in case of low-grade disease [134–141]. 
The majority of the biomarker studies could not be classified as unequivocal. This conclusion 
may be due to a loss of information (stage/grade/sensitivity/specificity) or due to a non-repre-
sentative patient population that overstates the sensitivity and specificity [130].
8. Lipids
There have been very few published analyses of lipids as potential biomarkers, although an 
increase in the serum of lipids and proteins associated with sialic acid were demonstrated to 
differentiate patients from healthy control groups, showing a sensitivity of around 80% and 
a specificity of 70% [142]. A rare variant of urothelial carcinoma has been characterized by large 
epithelial cells with an eccentric nucleus and vacuolated cytoplasm that resemble lipoblasts, 
which are also positive for cytokeratin 7, 20, CAM 5.2, and other proteins. Only in one publication 
on bladder tissue has the composition of fatty acids been taken into consideration; it was shown 
that there was an increase in the levels of stearic and oleic acid and a decrease in the level of ara-
chidonic acid in pathological tissue with respect to healthy tissue excised from the same patients 
[143]. In addition, the levels of some polyunsaturated fatty acids were significantly reduced, sug-
gesting an altered lipid metabolism occurring in vivo during human bladder tumor-genesis. The 
only attempt to determine lipid concentrations in urine was made more than 30 years ago in 
1985, comparing bladder tumor patients with healthy controls and additionally some patients 
with bacterial infections. It was shown that there was a marked difference in phospholipid levels 
compared to fatty acids with 100% specificity and 80% sensitivity. However, macrohematuria 
or infection can affect the results that subsequently appear similar to the tumor samples [142].
9. Isolated particle
9.1. Exosomes as possible marker
Exosomes are small membrane vesicles particles (30–100 nm) released by the cells into the 
extracellular environment and play different roles in many physiological situations like the 
immune response. Exosomes isolated from the urine of patients with muscle-invasive bladder 
cancer induced epithelial- to mesenchymal transition in urothelial cells [144].
9.2. Analysis of isolated virtosomes from voided urine
Circulating DNA has been isolated using chromatographic separation or by ultracentrifuga-
tion. In this way not only cell debris or particles, but also exosomes are eliminated. In the 
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supernatant obtained after ultracentrifugation are present virtosomes that are comprised of 
newly synthesized DNA, RNA, proteins, and phospholipids and are released from cells in 
a regulated fashion [145, 146]. In a research made on human lymphocytes in culture, it has 
been demonstrated that the cells released virtosomes that differ in composition in relation 
to the stimulation of proliferation made with phytohaemoagglutinin. The virtosomes pres-
ent in the medium may also be capable of influencing the non-stimulated lymphocytes and 
vice versa [146].
The isolation of virtosomes from voided urine of non-invasive bladder cancer patients has 
been attempted. The analysis of the material present in the voided urine and from the cell 
cytoplasm of the control group and the patients are reported in Table 2. The nucleic acid 
content was lower in the patient group, but the difference was not significant and was not 
confirmed by the cytoplasmic results.
The values shown in Table 2 are very different with respect to those obtained from healthy 
lymphocytes either in the culture medium or in the cytoplasm using the same procedure 
(Table 3), where a much larger proportion of protein and RNA was detected, and only a small 
proportion of phospholipid [146].
The chromatographic analysis of the phospholipids of the voided urine and cell cytoplasm 
did not show any significant difference between the control and patient groups, unless a small 
increase in the amount of sphingomyelin in the patient group is considered. However, the most 
important result was the presence of a large amount of lipids. Preliminary analysis highlighted 
some differences in the fatty acids that indicated the need for a more in depth analysis (Table 4).
Urine Cytoplasm
Controls Patients Controls Patients
Proteins % 1.5 ± 1.4 1.39 ± 1 0.223 ± 0.19 0.236 ± 0.259
DNA % 0.39 ± 0.31 0.1 ± 0.03 0.143 ± 0.79 0.17 ± 0.029
RNA % 0.09 ± 0.07 0.022 ± 0.007 0.096 ± 0.033 0.056 ± 0.030
PLs %(*) 98.5 ± 1.81 98.35 ± 0.95 99.4 ± 0.32 99.16 ± 0.23
(*) phospholipid.
Table 2. Composition of protein, DNA, RNA, and phospholipid in the voided urine and cell cytoplasm in the control 
and patient groups.
Medium Cytoplasm
Proteins % 37.91 41.01
DNA % 4.65 3.45
RNA % 53.41 35.09
PLs %(*) 3.94 19.90
(*) phospholipid.
Table 3. Composition of virtosomes isolated from lymphocytes.
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An analysis was also made using chromatographic and mass spectrometric separation by 
extracting lipids from 20 patients with non-invasive bladder cancer and 20 controls of similar 
ages (Figure 2).
Fatty acids presents in the virtosomes
Control % Low-grade tumor (Ta) %
Dodecanoate C12:0am== 3.3 μM 1.17 7.9 μM 3.24 �
Myristate C14:0 22.6 μM 8 15.3 μM 6.28 ↓
Pentadecanoate C15:0 27 μM 9.57 13.2 μM 5.4 ↓
Palmitate C16:0 98.6 μM 34.9 84.7 μM 34.78
Heptadecanoate C17:0 16 μM 5.67 11.8 μM 4.84
Linoleate C18:2n6 18.6 μM 6.59 12 μM 4.92
Oleate C18:1n9c 20.1 μM 7.12 21.2 μM 8.70 �
18-methyl nonadecanoate 
C19:0
1.9 μM 0.67 1 μM 0.41
Tricosanoic acid C23:0 0.9 μM 0.32 0.3 μM 0.12 ↓
Tetracosanoic acid C24:0 2.9 μM 1.02 0.8 μM 0.32 ↓
Stearate C18:0 70.2 μM 24.88 75.6 μM 31.04 �
Table 4. Preliminary analysis that highlighted differences in the fatty acids.
Figure 2. Lipid extraction from urine. Chromatoghraphy and mass-spectrometry of lipids extract from urine [148].
Bladder Cancer Markers and Recent Innovations
http://dx.doi.org/10.5772/67309
81
Two hundred and fifty lipids were analyzed and a significant difference was observed, in 
particular for 25 lipids that appear to be characteristic for the tumor patient. Their identifica-
tion may offer the possibility of a marker that appears to have sensitivity and a specificity of 
around 100% (Figure 3) [147].
10. Conclusions
The numerous publications clearly indicate how important it is to find markers for bladder 
cancer that may substitute cystoscopy and many efforts were made to find them. The symp-
toms of the tumor are not always significant and so it is necessary to determine new, specific 
and sensitive markers for an accurate diagnosis in order to prevent the diffusion of the pathol-
ogy and to determine the eventual patients at an early stage. This explains the continuous 
attempts to find good, non-invasive markers, possibly present in the urine. Ideally, they must 
be cheap so as to allow frequent repeated tests per patient and not technically complex for 
their use in all laboratories.
The existing markers (such as BTA or NMP22) are not considered sufficiently specific and sensi-
tive for a correct diagnosis and need to be supported by other tests, principally cystoscopy and 
cytology in which the interpretation depends much on the experience of the analyzer. Therefore, 
numerous attempts have been made to find other kinds of markers such as DNA mutations, 
DNA methylation, chromatin modifications, and specific proteins and, more recently, microR-
NAs present in the urine. To date, all results have been unsatisfactory given the complexity of 
the analysis and the limited specificity and/or sensitivity. Recently the composition of lipids in 
Figure 3. Partial least squares discriminant analysis (PLS-DA). Separation of lipids between patients and heathy controls 
[146].
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the voided urine of patient with non-invasive form and healthy control subjects showed some 
significant differences thus offering new markers with high sensitivity and specificity. If these 
preliminary data can be confirmed, a simple and inexpensive test may be produced that is use-
ful for both screening and prognosis.
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